Imipramine-mediated Suppression of EGFR Signaling Attenuates Invasive and Progressive Abilities of Hepatocellular Carcinoma Cells
Imipramine shows promise in enhancing HCC treatment outcomes in patients and targets the EGFR/MEK/ERK signaling pathway in in vitro HCC models, thereby augmenting the effectiveness of standard therapies.
Authors
- Fei‐Ting Hsu (ORCID: https://orcid.org/0000-0002-2153-340X)
- Dai-Cheng Dong (ORCID: https://orcid.org/0009-0002-5872-2447)
- PEN-AN LIAO
- Chun-Yu Fu (ORCID: https://orcid.org/0000-0002-5382-528X)
- Wei‐Ting Chen (ORCID: https://orcid.org/0009-0008-0547-9459)
- TZU-HSIANG LIN
Institutions
- China Medical University (TW)
- Central Taiwan University of Science and Technology (TW)
Publication Details
- Journal
- Anticancer Research
- Published
- 2024-12-01
- DOI
- https://doi.org/10.21873/anticanres.17360
- Citations
- 1
- Primary Topic
- Cancer, Stress, Anesthesia, and Immune Response
- Type
- article
- Field-Weighted Citation Impact
- 0.39